OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
October 21, 2022
Aragen’s new 12,000 ft² facility will include various dosage form capabilities, including oral solids, liquids, topicals, and films.
Recipharm’s new high speed filling line, designed for pre-filled syringes and cartridges, is expected to be operational by May 2023.
Aenova Group and Microcaps are partnering to enable new customized formulations for product development and life cycle management solutions.
October 15, 2022
How dry powder techniques can overcome limitations in biologics development and delivery to broaden routes of administration and global accessibility.
October 06, 2022
Sponsors should explore key considerations ahead of choosing a new outsourcing partner.
October 03, 2022
External expertise is beneficial in helping companies select the right tools at the right stages of development to ensure success.
October 02, 2022
Whether biologic manufacturers decide to outsource or develop products internally, the quality of a CDMO partnership is critical to success, especially for cell and gene therapy products.
September 02, 2022
By eliminating the waste involved in traditional approaches to project set-up and execution, integrated project delivery helps innovators in the European life sciences market meet their fast-track delivery targets.
It is important to understand regulatory requirements and study challenges to develop and validate the appropriate methods for a bioanalytical study program at the clinical stage.
September 01, 2022
Pharmaceutical Technology editors interview aseptic and sterilization experts from Watson-Marlow Fluid Technology Solutions and Cherwell—diving into sterilization, aseptic processing, and the revised EU GMP Annex 1 guidance.
